June 3, 2022 – Biogen Presents Promising Data from the Phase 3 Tofersen Study

The results from the Phase 3 VALOR Trial and Open-Label Extension were presented at the 20th meeting of the European Network for the Cure of Amyotrophic Lateral Sclerosis (ENCALS) in Edinburgh, Scotland. The presentation slides can be found here.

The data shows that Tofersen use is associated with clinically meaningful benefits in people with SOD1 ALS.

Biogen's Press Release: https://investors.biogen.com/news-releases/news-release-details/new-12-month-tofersen-data-presented-encals-meeting-show